mFOLFIRINOX Treatment Regimen

DRUG4 trials

Sponsors

Medical College of Wisconsin, Hopital Foch, Zhejiang University, Oncolytics Biotech

Conditions

Anal Cancer MetastaticPancreas NeoplasmsPancreatic CancerPancreatic Cancer MetastaticPancreatic Cancer Non-resectableSquamous Cell Carcinoma of the Anus Stage UnspecifiedUnresectable Pancreatic Carcinoma

Phase 1

Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.

Not yet recruitingNCT06888648

Zhejiang UniversityPancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable

Start: 2025-04-01End: 2028-04-01Target: 30Updated: 2025-03-21

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

RecruitingNCT07280377

Oncolytics BiotechAnal Cancer Metastatic, Pancreatic Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified +1

Start: 2021-10-27End: 2028-12-31Target: 122Updated: 2025-12-12

Phase 2

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

RecruitingNCT04683315

Medical College of WisconsinPancreatic Cancer

Start: 2021-04-01End: 2028-12-31Target: 84Updated: 2026-03-05

DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer

RecruitingNCT06757244

Hopital FochPancreas Neoplasms

Start: 2025-02-18End: 2028-02-18Target: 35Updated: 2025-03-18

Related Papers

Cross-platform comparison of gene expression-based cancer molecular subtyping reveals discrepancies with exome capture methods.

2025-12-20

Purity Independent Subtyping of Tumors (PurIST) Pancreatic Cancer Classifier: Analytic Validation of a 16-RNA Expression Signature Distinguishing Basal and Classical Subtypes.

2024-08-221 citations